US Stock MarketDetailed Quotes

TLX Telix Pharmaceuticals

Watchlist
  • 15.150
  • +0.450+3.06%
Close Nov 25 16:00 ET
5.33BMarket Cap166.48P/E (TTM)

About Telix Pharmaceuticals Company

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

Company Profile

SymbolTLX
Company NameTelix Pharmaceuticals
Founded2017
CEODr. Christian Behrenbruch, D.Phil.,J.D.
MarketNASDAQ
Employees234
Securities TypeDR
ADS Ratio1.0 : 1.0
Fiscal Year Ends12-31
Address55 Flemington Road,Suite 401,North Melbourne
CityMelbourne
ProvinceVictoria (VIC)
CountryAustralia
Zip Code3051
Phone61-3-9093-3855
Websitehttp://www.telixpharma.com

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Christian Behrenbruch, D.Phil.,J.D.
  • Director, Managing Director and Group Chief Executive Officer
  • --
  • Darren Smith
  • Group Chief Financial Officer
  • --
  • Darren Patti
  • Group Chief Operating Officer
  • --
  • David Cade
  • Group Chief Medical Officer
  • --
  • H. Kevin McCann, A.O.,B.A.,L.L.M.
  • Non-Executive Chairman of the Board
  • --
  • Dr. Mark Nelson, M.Phil,PhD
  • Independent Director
  • --
  • Tiffany P. Olson, M.B.A.
  • Independent Director
  • --
  • Jann Skinner, B.Com,F.C.A.
  • Independent Director
  • --

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data